key: cord-0913215-x2e13mqu authors: Warner, Matthew A.; Patel, Prakash A.; Hensley, Nadia B.; Mazzeffi, Michael title: COVID-19 Related Blood Shortages and Cardiac Surgery: Do We Have Too Many Eggs in One Basket? date: 2022-02-23 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2022.02.021 sha: d7e6c887cd3d4f0c9859b1b7a692bb915888409c doc_id: 913215 cord_uid: x2e13mqu nan The American Red Cross, which supplies approximately 40% of the nation's blood supply, estimates the demand for red blood cells (RBCs) is approximately 14 million units per year. 3 In addition, 2 million platelet and 2.5 million plasma units are transfused annually. Surgical patients, particularly cardiac surgical patients, continue to be a major consumer of allogeneic blood products. There are over 300,000 cardiac surgical procedures performed with cardiopulmonary bypass (CPB) each year in the US, with conservative estimates suggesting that at least one-third of adult cardiac surgery patients are transfused perioperatively. 4, 5 However, transfusion risk varies greatly with surgical complexity, and transfusion rates for complex operations (e.g., combined valve replacement and coronary artery bypass grafting) exceed 80%. 6 Given the trend of increasing surgical complexity, it is likely that allogeneic transfusion rates will remain high in cardiac surgery for the foreseeable future. The coronavirus disease-2019 (COVID-19) pandemic has dramatically impacted nearly all aspects of life in the US, including our national blood system. Supply chain disturbances have been numerous, affecting the building industry, auto industry, food industry, and healthcare. In June 2020, industry leaders from across the US were surveyed regarding these challenges, with 93% of respondents acknowledging a need to make supply chains more "flexible, agile, and resilient". 7 These disturbances have magnified US blood collection challenges, leading to blood shortages that have progressively worsened throughout the pandemic. In this setting, the US Department of Health and Human Services (HHS) issued a report to Congress on the adequacy of our national blood supply, describing multiple "stressors" in the current system (Table 1) . These include a lack of "real-time" monitoring of our national blood inventory, reliance on a loosely connected system of non-profit blood centers and hospital-based collection centers without robust integration or central coordination, an aging donor pool, disparate local collection and supply models, and regulations that do not promote innovation and rapid adoption of new technology. 8 By late 2021, numerous blood collections across the nation, including critically important mobile drives at high school and college campuses, had been cancelled because of COVID-19. Staffing shortages and associated social and economic disturbances resulted in a 10% drop in US blood collections from pre-pandemic levels. When coupled with high volumes of surgical and intensive care unit admissions, this resulted in depletion of local and regional blood inventories. The American Red Cross and other blood collection organizations offered numerous incentives to attract donors to available blood donation sites including opportunities to win Super Bowl tickets, luxury travel packages to popular music festivals, gift cards, and home electronic devices. Nevertheless, blood shortages worsened, and in January 2022 the American Red Cross declared a "National Blood Emergency" for the first time in its history. 9 In response, the American Medical Association, American Nurses Association, and While strengthening the US blood supply is critically important and receives appropriate media coverage, far less attention is given to equally important efforts to decrease the demand for allogeneic blood products. In light of the national blood crisis, coupled with the multitude of well-described benefits to patients and the broader healthcare system that accompany reduction in allogeneic transfusion, it is past time for hospitals across the nation, including cardiac surgery programs, to evaluate current transfusion practices and further invest in evidence-based patient blood management (PBM). PBM can be loosely defined as evidence-based clinical practice and educational tools to optimize the blood health of each patient, minimize transfusion exposure, and improve clinical outcomes. These initiatives are a win-win for patients and hospitals -conserving blood resources for those most in need, reducing transfusion, expenditures and waste, and improving patient outcomes. 10, 11 In 2021, the Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists published an updated joint guideline outlining contemporary PBM practices in cardiac surgery. 12 In the guideline, the authors provide multiple 12 Simply stated, these evidencebased tools are readily available in nearly all cardiac surgery practices to augment red cell production, prevent and treat coagulopathy, and minimize perioperative bleeding, thereby reducing the need for allogenic transfusion. Beyond these immediately available interventions, there are other long-term aspirational goals, which may help to stabilize the US blood supply ( Table 2 ). These include efforts to prolong the shelf-life of blood components (e.g., mitigation strategies for the RBC storage lesion, delayed cold-storage of platelets), enhancing research into RBC-like products (e.g., hemoglobin-based oxygen carriers, encapsulated hemoglobin products) and pooled products with longer storage durations (e.g. cryopreserved platelets, freeze dried plasma), and expanding use of fibrinogen concentrates and factor concentrates for the treatment of acquired coagulation abnormalities. Further, it is essential to establish a strong pool of recurring blood donors rather than relying on surges in one-time donations in response to critical events, as such highly publicized calls for donations may be unnecessary to meet current transfusion demand, overwhelm local blood collection capacity, and ultimately lead to increased blood waste. 13 While these aspirational goals will take years to achieve, common-sense PBM tools to decrease blood demand and improve the blood health of each patient are available for broad adoption now. Each individual provider (cardiothoracic anesthesiologist, cardiac surgeon, intensivist) can have an immediate impact on ongoing blood shortages by critically evaluating the appropriateness of each transfusion, becoming a recurrent blood donor if they are eligible, and by advocating for PBM initiatives in their own institution. Although the national blood crisis will continue to challenge our healthcare system for the foreseeable future, it should serve as a unifying call to improve our blood banking systems, promote coordination between diverse blood collection and distribution organizations, and in invest in research, quality improvement, and practice optimization efforts to reduce blood demand by embracing the core principles of PBM. Lozada Create novel regulatory approaches to foster innovation and move important technology into practice more quickly Create a public-private partnership that in coordination with FDA reviews how current regulations impact innovation, safety, and outcomes Revenue losses and negative balance sheets for many blood collection centers Move away from treatment of blood as a commodity and move towards treatment of nation's blood supply as a public health program The United States' potential blood donor pool: updating the prevalence of donor-exclusion factors on the pool of potential donors Slowing decline in blood collection and transfusion in the United States -2017 American Red Cross: Blood Supply Statistics The Effect of COVID-19 on Adult Cardiac Surgery in the United States in 717 103 Patients Trends in blood utilization in United States cardiac surgical patients The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2019 Update on Outcomes and Quality McKinsey and Company: How COVID-19 is Reshaping Supply Chains United States Department of Health and Human Services: Adequacy of the National Blood Supply: Report to Congress Red Cross Declares First-ever Blood Crisis amid Omicron Surge Patient Blood Management Program Improves Blood Use and Clinical Outcomes in Orthopedic Surgery Implementation of a Comprehensive Patient Blood Management Program for Hospitalized Patients at a Large United States Medical Center STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Funding: MAW's research is supported through K23HL153310 from the National Heart Lung and Blood Institute (NHLBI). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH). Disclosure: MAW and PAP serve on the Board of Directors for the Society for the Advancement of Patient Blood Management. MAW, NBH and MM serve on the American Society of Anesthesiologists Committee on Patient Blood Management. NBH and MM are the scientific advisory board for Octapharma USA, which is involved in patient blood management.